Dostarlimab的药理学研究进展

A. Roy, Akash Chaurasiya
{"title":"Dostarlimab的药理学研究进展","authors":"A. Roy, Akash Chaurasiya","doi":"10.18579/jopcr/v21i2.2","DOIUrl":null,"url":null,"abstract":"Dostarlimab is a humanised anti-PD-1 immunoglobulin (IgG4) monoclonal antibody (mAb). It has a high affinity for the PD-1 receptor and effectively inhibits interactions with PD-L1 and PD-L2 by blocking their binding to the PD-1 receptor. Programmed cell death 1 (PD-1) is an immunological checkpoint receptor that transmits inhibitory signals to limit local inflammatory responses and preserve self-tolerance. It is found on antigen-activated and fatigued T cells. When the PD-1 receptor binds to the tumor-expressed ligands PD-L1 and PD-L2, T-cell proliferation and cytokine production are suppressed. Keywords: Dostarlimab, PD­1 immunoglobulin, T - cell proliferation","PeriodicalId":16706,"journal":{"name":"Journal of Pharmaceutical Research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacology of Dostarlimab: A Review\",\"authors\":\"A. Roy, Akash Chaurasiya\",\"doi\":\"10.18579/jopcr/v21i2.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dostarlimab is a humanised anti-PD-1 immunoglobulin (IgG4) monoclonal antibody (mAb). It has a high affinity for the PD-1 receptor and effectively inhibits interactions with PD-L1 and PD-L2 by blocking their binding to the PD-1 receptor. Programmed cell death 1 (PD-1) is an immunological checkpoint receptor that transmits inhibitory signals to limit local inflammatory responses and preserve self-tolerance. It is found on antigen-activated and fatigued T cells. When the PD-1 receptor binds to the tumor-expressed ligands PD-L1 and PD-L2, T-cell proliferation and cytokine production are suppressed. Keywords: Dostarlimab, PD­1 immunoglobulin, T - cell proliferation\",\"PeriodicalId\":16706,\"journal\":{\"name\":\"Journal of Pharmaceutical Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.18579/jopcr/v21i2.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18579/jopcr/v21i2.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

Dostarlimab是一种人源化抗PD-1免疫球蛋白(IgG4)单克隆抗体(mAb)。它对PD-1受体具有高亲和力,并通过阻断它们与PD-1受体的结合而有效抑制与PD-L1和PD-L2的相互作用。程序性细胞死亡1(PD-1)是一种免疫检查点受体,它传递抑制信号以限制局部炎症反应并保持自我耐受。它存在于抗原激活和疲劳的T细胞上。当PD-1受体与肿瘤表达的配体PD-L1和PD-L2结合时,T细胞增殖和细胞因子产生受到抑制。关键词:Dostarlimab,PD-1免疫球蛋白,T细胞增殖
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pharmacology of Dostarlimab: A Review
Dostarlimab is a humanised anti-PD-1 immunoglobulin (IgG4) monoclonal antibody (mAb). It has a high affinity for the PD-1 receptor and effectively inhibits interactions with PD-L1 and PD-L2 by blocking their binding to the PD-1 receptor. Programmed cell death 1 (PD-1) is an immunological checkpoint receptor that transmits inhibitory signals to limit local inflammatory responses and preserve self-tolerance. It is found on antigen-activated and fatigued T cells. When the PD-1 receptor binds to the tumor-expressed ligands PD-L1 and PD-L2, T-cell proliferation and cytokine production are suppressed. Keywords: Dostarlimab, PD­1 immunoglobulin, T - cell proliferation
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
4 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信